m-formylcinnamic acid | 56030-23-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: m-formylcinnamic acid
• 英文别名: 3-(3-formylphenyl)acrylic acid；3-Formyl cinnamic acid；3-Formylcinnamic acid；3-(3-formylphenyl)prop-2-enoic acid
• CAS: 56030-23-0
• 化学式: C₁₀H₈O₃
• 分子量: 176.172
• InChiKey: PQXAPANLBKXEKT-UHFFFAOYSA-N

物化性质

• 沸点：
  364.0±25.0 °C(Predicted)
• 密度：
  1.288±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  m-formylcinnamic acid 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 3-(N,N-Dimethylaminomethyl)-benzolbutannitril
  参考文献：
  名称：

  DE2821410

  摘要：

  公开号：

文献信息

• Novel Myocyte Enhancer Factor 2 (MEF2) modulators
  申请人：STANDARD LLC

  公开号：US20190241504A1

  公开（公告）日：2019-08-08

  The present disclosure provides novel compounds capable of functioning as Myoctye Enhancer Factor 2 (MEF2) modulators, as well as compositions, pharmaceutical formulations, methods of synthesis and kits. Also provided are methods of treating a condition regulatable by MEF2 and/or MEF2 cofactors using the compounds, compositions, pharmaceutical formulations, and kits provided herein.

  本公开提供了能够作为肌肉细胞增强因子2（MEF2）调节剂发挥作用的新化合物，以及组合物、药物配方、合成方法和试剂盒。还提供了使用本文提供的化合物、组合物、药物配方和试剂盒治疗可通过MEF2和/或MEF2辅因子调节的疾病的方法。
• CBI analogues of the duocarmycins and CC-1065
  申请人：Boger L. Dale

  公开号：US20050026987A1

  公开（公告）日：2005-02-03

  An extensive series of CBI analogues of the duocarmycins and CC-1065 exploring substituent effects within the first indole DNA binding subunit is detailed. In general, substitution at the indole C5 position led to cytotoxic potency enhancements that can be ≧1000-fold providing simplified analogues containing a single DNA binding subunit that are more potent (IC 50 =2-3 pM) than CBI-TMI, duocarmycin SA, or CC-1065. The increases in cytotoxicity correlate well with accompanying increases in the rate and efficiency of DNA alkylation. This effect is more pronounced with the CBI versus DSA or CPI based analogues. Moreover, this effect is largely insensitive to the electronic character of the C5 substituent but is sensitive to the size, rigid length, and shape (sp, sp 2 , sp 3 hybridization) of this substituent consistent with expectation that the impact is due simply to its presence.

  一系列广泛的CBI类似物，包括二聚卡蜜素和CC-1065的类似物，探索了第一个吲哚DNA结合亚基中取代基效应的细节。一般来说，在吲哚C5位置的取代导致细胞毒性增强，可以达到≧1000倍，提供了更强效（IC50=2-3 pM）的含有单个DNA结合亚基的简化类似物，比CBI-TMI、二聚卡蜜素SA或CC-1065更有效。细胞毒性增加与DNA烷基化速率和效率的增加密切相关。与基于DSA或CPI的类似物相比，这种效应在CBI类似物中更为显著。此外，这种效应对于C5取代基的电子性质不太敏感，但对于取代基的大小、刚性长度和形状（sp、sp2、sp3杂化）敏感，这与预期一致，即这种影响仅仅是由于其存在。
• [EN] ANTICANCER AGENTS<br/>[FR] AGENTS ANTICANCÉREUX
  申请人：UNIV MINNESOTA

  公开号：WO2009018344A1

  公开（公告）日：2009-02-05

  The invention provides a compound of the invention, which is a compound of formula A-X-L-B, or a salt thereof, as well as compositions comprising a compound of the invention, and therapeutic methods that include the administration of a compound of the invention. The compounds of the invention are useful as therapeutic agents for the treatment of diseases such as cancer.

  该发明提供了一种该发明的化合物，该化合物为A-X-L-B式的化合物或其盐，以及包含该发明的化合物的组合物，以及包括给予该发明的化合物的治疗方法。该发明的化合物可用作治疗剂，用于治疗癌症等疾病。
• Heterocyclic derivatives as HDAC inhibitors
  申请人：DAC S.r.l.

  公开号：EP2133334A1

  公开（公告）日：2009-12-16

  This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; R1 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1 C6 haloalkoxy; R2, R3 are, independently, hydrogen; C1-C6 alkyl; aryl; or taken together with the carbon atoms to which they are bound form a bridged bicyclic ring or a fused heterocycle; X is CH or nitrogen; Y is a bond, oxygen, (CH2)mCR4R5(CH2)n, or (CH2)oNR6(CH2)p; m, n, o, p, R4, R5 and R6 are as further defined in the specification; and pharmaceutical acceptable salts thereof.

  这项发明涉及新的组蛋白去乙酰化酶抑制剂，其通式如下（I）：其中：虚线是可选的额外键；R1是氢、卤素、C1-C6烷基、C1-C6烷氧基、C1-C6卤烷基或C1-C6卤烷氧基；R2、R3分别是氢、C1-C6烷基、芳基；或者与它们相结合的碳原子形成桥接的双环或融合的杂环；X是CH或氮；Y是键、氧、（CH2）mCR4R5（CH2）n、或（CH2）oNR6（CH2）p；m、n、o、p、R4、R5和R6如规范中进一步定义；以及其药用可接受盐。
• Cinnamic, Phenylpropiolic and Phenylpropanoic Acid Derivatives Useful as Anti-Tumor Agents
  申请人：Pisano Claudio

  公开号：US20080194659A1

  公开（公告）日：2008-08-14

  Cinnamic and phenylpropiolic acid derivatives of formula (I) having antitumour and chemo sensitizing activity are described. Also described are pharmaceutical compositions containing the above-mentioned compounds, for the treatment of tumours.

  描述了具有抗肿瘤和化疗增敏活性的式（I）的肉桂酸和苯基丙炔酸衍生物。还描述了含有上述化合物的药物组合物，用于治疗肿瘤。